Udaya Kompella
Concepts (714)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug Delivery Systems | 39 | 2021 | 301 | 8.420 |
Why?
| Nanoparticles | 33 | 2022 | 315 | 5.710 |
Why?
| Retina | 27 | 2020 | 266 | 4.800 |
Why?
| Sulfonamides | 17 | 2017 | 447 | 3.430 |
Why?
| Eye Diseases | 11 | 2021 | 76 | 3.370 |
Why?
| Choroid | 14 | 2020 | 47 | 2.970 |
Why?
| Pyrazoles | 14 | 2014 | 362 | 2.650 |
Why?
| Eye | 12 | 2017 | 101 | 2.570 |
Why?
| Drug Carriers | 14 | 2019 | 113 | 2.330 |
Why?
| Triptorelin Pamoate | 14 | 2009 | 19 | 2.310 |
Why?
| Vascular Endothelial Growth Factor A | 23 | 2017 | 503 | 2.260 |
Why?
| Polyglycolic Acid | 16 | 2015 | 43 | 2.160 |
Why?
| Lactic Acid | 17 | 2015 | 275 | 2.090 |
Why?
| Delayed-Action Preparations | 17 | 2020 | 159 | 2.050 |
Why?
| Ophthalmic Solutions | 11 | 2017 | 66 | 2.040 |
Why?
| Budesonide | 8 | 2020 | 87 | 1.920 |
Why?
| Pharmaceutical Preparations | 8 | 2022 | 169 | 1.860 |
Why?
| Gene Transfer Techniques | 8 | 2014 | 148 | 1.830 |
Why?
| Pigment Epithelium of Eye | 11 | 2012 | 34 | 1.820 |
Why?
| Sclera | 9 | 2012 | 35 | 1.760 |
Why?
| Animals | 116 | 2023 | 32104 | 1.730 |
Why?
| Diabetes Mellitus, Experimental | 9 | 2018 | 161 | 1.720 |
Why?
| Diabetic Retinopathy | 8 | 2018 | 149 | 1.720 |
Why?
| Particle Size | 16 | 2020 | 319 | 1.680 |
Why?
| Rabbits | 28 | 2022 | 752 | 1.490 |
Why?
| Conjunctiva | 14 | 2009 | 51 | 1.480 |
Why?
| Enzyme Inhibitors | 10 | 2011 | 757 | 1.450 |
Why?
| Tandem Mass Spectrometry | 8 | 2022 | 414 | 1.450 |
Why?
| Retinal Pigment Epithelium | 7 | 2013 | 58 | 1.430 |
Why?
| Nanostructures | 4 | 2019 | 99 | 1.420 |
Why?
| Blood-Retinal Barrier | 6 | 2013 | 13 | 1.410 |
Why?
| Rats | 34 | 2020 | 5033 | 1.370 |
Why?
| Dexamethasone | 4 | 2020 | 316 | 1.360 |
Why?
| Sulfones | 6 | 2012 | 98 | 1.350 |
Why?
| Vitreous Body | 13 | 2020 | 102 | 1.340 |
Why?
| Cyclooxygenase Inhibitors | 6 | 2008 | 72 | 1.320 |
Why?
| Rats, Sprague-Dawley | 26 | 2020 | 2262 | 1.280 |
Why?
| Drug Compounding | 6 | 2020 | 89 | 1.260 |
Why?
| Capillary Permeability | 6 | 2011 | 138 | 1.250 |
Why?
| Melanins | 4 | 2012 | 18 | 1.250 |
Why?
| Polymers | 8 | 2013 | 463 | 1.150 |
Why?
| Anti-Inflammatory Agents | 6 | 2020 | 448 | 1.150 |
Why?
| Cattle | 18 | 2021 | 935 | 1.140 |
Why?
| Glucocorticoids | 6 | 2021 | 552 | 1.130 |
Why?
| Receptors, LHRH | 5 | 2009 | 17 | 1.110 |
Why?
| Glycine | 6 | 2009 | 156 | 1.100 |
Why?
| Aldehyde Reductase | 5 | 2007 | 24 | 1.090 |
Why?
| Cornea | 10 | 2015 | 107 | 1.060 |
Why?
| RNA, Small Interfering | 5 | 2017 | 544 | 1.040 |
Why?
| Nanotechnology | 5 | 2019 | 115 | 1.030 |
Why?
| Nasal Mucosa | 6 | 2009 | 94 | 1.020 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2012 | 301 | 1.010 |
Why?
| Celecoxib | 14 | 2014 | 38 | 0.980 |
Why?
| Intercellular Signaling Peptides and Proteins | 5 | 2013 | 350 | 0.970 |
Why?
| Epithelial Cells | 8 | 2016 | 961 | 0.960 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 216 | 0.950 |
Why?
| alpha-Crystallin B Chain | 2 | 2022 | 18 | 0.940 |
Why?
| Retinal Degeneration | 3 | 2020 | 30 | 0.910 |
Why?
| Dendrimers | 4 | 2012 | 13 | 0.900 |
Why?
| Chromatography, Liquid | 7 | 2022 | 347 | 0.890 |
Why?
| Tomography, Optical Coherence | 2 | 2021 | 128 | 0.880 |
Why?
| Gonadotropin-Releasing Hormone | 5 | 2006 | 193 | 0.850 |
Why?
| Intraocular Pressure | 4 | 2020 | 277 | 0.850 |
Why?
| Choroidal Neovascularization | 6 | 2017 | 44 | 0.840 |
Why?
| Cyprinidae | 1 | 2022 | 19 | 0.840 |
Why?
| Cyclooxygenase 2 Inhibitors | 6 | 2014 | 20 | 0.840 |
Why?
| Sotalol | 1 | 2022 | 4 | 0.830 |
Why?
| Insulins | 1 | 2022 | 32 | 0.800 |
Why?
| Awards and Prizes | 1 | 2022 | 56 | 0.790 |
Why?
| Neuroprotective Agents | 1 | 2022 | 105 | 0.790 |
Why?
| Lymphocyte Function-Associated Antigen-1 | 2 | 2012 | 34 | 0.780 |
Why?
| Ophthalmoscopes | 1 | 2021 | 2 | 0.780 |
Why?
| Viscosity | 2 | 2020 | 83 | 0.780 |
Why?
| Glaucoma | 4 | 2020 | 204 | 0.780 |
Why?
| Tissue Distribution | 10 | 2019 | 324 | 0.770 |
Why?
| Administration, Topical | 10 | 2020 | 137 | 0.770 |
Why?
| Administration, Ophthalmic | 8 | 2021 | 14 | 0.760 |
Why?
| Peptides | 5 | 2022 | 864 | 0.740 |
Why?
| Molecular Chaperones | 3 | 2022 | 157 | 0.730 |
Why?
| Water | 3 | 2019 | 412 | 0.720 |
Why?
| Lens, Crystalline | 4 | 2011 | 96 | 0.720 |
Why?
| Intravitreal Injections | 10 | 2020 | 46 | 0.710 |
Why?
| Infusion Pumps, Implantable | 1 | 2020 | 20 | 0.710 |
Why?
| Bleomycin | 3 | 2018 | 232 | 0.700 |
Why?
| Peptide Fragments | 4 | 2013 | 675 | 0.700 |
Why?
| Antihypertensive Agents | 2 | 2014 | 432 | 0.700 |
Why?
| Injections, Intraocular | 3 | 2017 | 10 | 0.690 |
Why?
| Endothelial Growth Factors | 4 | 2003 | 50 | 0.680 |
Why?
| Lymphokines | 4 | 2003 | 115 | 0.680 |
Why?
| Mitochondria | 3 | 2022 | 750 | 0.670 |
Why?
| Genetic Therapy | 5 | 2014 | 260 | 0.670 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 667 | 0.670 |
Why?
| beta-Cyclodextrins | 3 | 2004 | 28 | 0.670 |
Why?
| Lung Injury | 2 | 2018 | 199 | 0.660 |
Why?
| Fluorescent Dyes | 5 | 2018 | 304 | 0.660 |
Why?
| Albumins | 2 | 2019 | 91 | 0.650 |
Why?
| Macular Degeneration | 5 | 2017 | 152 | 0.650 |
Why?
| Ephrin-A2 | 1 | 2018 | 3 | 0.650 |
Why?
| Microscopy, Confocal | 8 | 2020 | 299 | 0.650 |
Why?
| Retinal Diseases | 5 | 2014 | 77 | 0.640 |
Why?
| Lung | 5 | 2018 | 3673 | 0.630 |
Why?
| Chromatography, High Pressure Liquid | 12 | 2013 | 477 | 0.630 |
Why?
| Cell Line | 17 | 2018 | 2651 | 0.630 |
Why?
| Biological Transport | 9 | 2012 | 375 | 0.630 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 90 | 0.610 |
Why?
| Biological Availability | 9 | 2020 | 119 | 0.610 |
Why?
| Lipid Bilayers | 1 | 2019 | 101 | 0.610 |
Why?
| Fluorescein-5-isothiocyanate | 4 | 2016 | 37 | 0.600 |
Why?
| Microspheres | 4 | 2012 | 122 | 0.590 |
Why?
| Area Under Curve | 7 | 2020 | 277 | 0.580 |
Why?
| Fluorescein | 4 | 2018 | 27 | 0.580 |
Why?
| Needles | 1 | 2017 | 52 | 0.580 |
Why?
| Permeability | 9 | 2018 | 150 | 0.580 |
Why?
| Technology, Pharmaceutical | 2 | 2010 | 19 | 0.580 |
Why?
| Retinitis Pigmentosa | 2 | 2014 | 16 | 0.550 |
Why?
| Rats, Inbred BN | 8 | 2011 | 53 | 0.550 |
Why?
| Antineoplastic Agents | 6 | 2022 | 1893 | 0.550 |
Why?
| Cataract | 2 | 2011 | 185 | 0.550 |
Why?
| Cephalosporins | 3 | 2002 | 26 | 0.530 |
Why?
| Nanocapsules | 2 | 2013 | 8 | 0.530 |
Why?
| Electric Impedance | 4 | 2014 | 99 | 0.510 |
Why?
| Endothelial Cells | 3 | 2018 | 696 | 0.510 |
Why?
| Dinoprostone | 3 | 2009 | 186 | 0.500 |
Why?
| Epithelium, Corneal | 6 | 2018 | 37 | 0.500 |
Why?
| Disease Models, Animal | 15 | 2018 | 3580 | 0.500 |
Why?
| Humans | 64 | 2023 | 115741 | 0.490 |
Why?
| Pyridones | 2 | 2013 | 125 | 0.490 |
Why?
| Exfoliation Syndrome | 1 | 2014 | 10 | 0.490 |
Why?
| Leukostasis | 2 | 2011 | 3 | 0.490 |
Why?
| RNA, Messenger | 15 | 2012 | 2574 | 0.480 |
Why?
| Chemical Phenomena | 2 | 2011 | 81 | 0.460 |
Why?
| Light | 2 | 2013 | 337 | 0.450 |
Why?
| Male | 44 | 2020 | 56050 | 0.450 |
Why?
| Mice | 23 | 2023 | 15052 | 0.450 |
Why?
| Eye Proteins | 2 | 2012 | 73 | 0.440 |
Why?
| Transferrin | 3 | 2009 | 40 | 0.440 |
Why?
| Cell Proliferation | 8 | 2017 | 2194 | 0.440 |
Why?
| Posterior Eye Segment | 1 | 2013 | 2 | 0.440 |
Why?
| Chloroquine | 2 | 2012 | 52 | 0.440 |
Why?
| Serum Albumin, Bovine | 1 | 2013 | 65 | 0.440 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2018 | 1137 | 0.430 |
Why?
| Pyrimidines | 2 | 2017 | 376 | 0.430 |
Why?
| Capsid Proteins | 1 | 2013 | 69 | 0.430 |
Why?
| Glaucoma, Open-Angle | 1 | 2014 | 95 | 0.430 |
Why?
| Nanomedicine | 1 | 2013 | 28 | 0.430 |
Why?
| Poloxamer | 2 | 2002 | 12 | 0.430 |
Why?
| Salicylic Acid | 1 | 2012 | 8 | 0.420 |
Why?
| Pulmonary Fibrosis | 2 | 2013 | 330 | 0.420 |
Why?
| Adenoviridae | 1 | 2013 | 186 | 0.420 |
Why?
| Fluocinolone Acetonide | 2 | 2011 | 16 | 0.420 |
Why?
| Phenylalanine | 1 | 2012 | 58 | 0.420 |
Why?
| Geographic Atrophy | 1 | 2013 | 49 | 0.420 |
Why?
| Cyclooxygenase 2 | 4 | 2012 | 164 | 0.410 |
Why?
| Drug Implants | 3 | 2020 | 71 | 0.410 |
Why?
| Adrenergic beta-Antagonists | 4 | 2011 | 294 | 0.410 |
Why?
| Chlorides | 4 | 1998 | 130 | 0.410 |
Why?
| Carbon Dioxide | 4 | 2013 | 211 | 0.400 |
Why?
| Adrenal Cortex Hormones | 3 | 2021 | 509 | 0.400 |
Why?
| Corneal Neovascularization | 4 | 2015 | 12 | 0.400 |
Why?
| Drug Liberation | 3 | 2021 | 25 | 0.400 |
Why?
| Bronchodilator Agents | 2 | 2005 | 249 | 0.390 |
Why?
| Injections | 8 | 2011 | 161 | 0.390 |
Why?
| Probenecid | 2 | 2009 | 7 | 0.390 |
Why?
| Tyrosine | 1 | 2012 | 219 | 0.390 |
Why?
| STAT1 Transcription Factor | 1 | 2011 | 64 | 0.390 |
Why?
| Antioxidants | 2 | 2014 | 533 | 0.390 |
Why?
| Thiazines | 1 | 2011 | 9 | 0.390 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2009 | 104 | 0.380 |
Why?
| Oxidative Stress | 5 | 2021 | 1093 | 0.380 |
Why?
| Bevacizumab | 4 | 2017 | 118 | 0.380 |
Why?
| Macular Edema | 1 | 2011 | 35 | 0.380 |
Why?
| Mitochondrial Diseases | 1 | 2011 | 77 | 0.370 |
Why?
| Absorbable Implants | 2 | 2020 | 34 | 0.370 |
Why?
| Oligonucleotides, Antisense | 3 | 2009 | 100 | 0.370 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2012 | 930 | 0.360 |
Why?
| Polyglactin 910 | 2 | 2012 | 10 | 0.360 |
Why?
| Thiophenes | 1 | 2011 | 108 | 0.360 |
Why?
| Poly G | 1 | 2010 | 1 | 0.360 |
Why?
| Suspensions | 3 | 2020 | 30 | 0.360 |
Why?
| Diclofenac | 2 | 2009 | 14 | 0.360 |
Why?
| Trabecular Meshwork | 1 | 2011 | 77 | 0.350 |
Why?
| Fluoroquinolones | 1 | 2010 | 41 | 0.350 |
Why?
| Micelles | 1 | 2010 | 34 | 0.350 |
Why?
| Solvents | 5 | 2013 | 108 | 0.350 |
Why?
| Solubility | 5 | 2011 | 226 | 0.350 |
Why?
| Retinal Neovascularization | 4 | 2015 | 20 | 0.350 |
Why?
| Vascular Diseases | 1 | 2012 | 230 | 0.350 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2009 | 10 | 0.340 |
Why?
| Drug Stability | 6 | 2011 | 152 | 0.340 |
Why?
| Chorioallantoic Membrane | 1 | 2009 | 3 | 0.330 |
Why?
| Gene Expression | 5 | 2018 | 1436 | 0.330 |
Why?
| Porosity | 4 | 2013 | 93 | 0.330 |
Why?
| Cell Survival | 6 | 2013 | 1024 | 0.330 |
Why?
| Lung Neoplasms | 5 | 2017 | 2207 | 0.330 |
Why?
| Taxoids | 1 | 2009 | 94 | 0.320 |
Why?
| Quantitative Structure-Activity Relationship | 1 | 2008 | 13 | 0.320 |
Why?
| Plasmids | 5 | 2017 | 345 | 0.320 |
Why?
| Receptor, EphA2 | 2 | 2018 | 19 | 0.320 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1870 | 0.310 |
Why?
| Spectroscopy, Fourier Transform Infrared | 4 | 2010 | 76 | 0.310 |
Why?
| Models, Animal | 2 | 2020 | 350 | 0.310 |
Why?
| Endothelium, Corneal | 2 | 2021 | 15 | 0.310 |
Why?
| DNA-Binding Proteins | 3 | 2023 | 1316 | 0.310 |
Why?
| Pharmacokinetics | 4 | 2012 | 26 | 0.310 |
Why?
| Injections, Intravenous | 5 | 2017 | 204 | 0.310 |
Why?
| Eye Color | 1 | 2008 | 3 | 0.310 |
Why?
| Protein-Tyrosine Kinases | 1 | 2011 | 396 | 0.310 |
Why?
| Bruch Membrane | 2 | 2011 | 6 | 0.300 |
Why?
| Vascular Endothelial Growth Factors | 5 | 2011 | 61 | 0.300 |
Why?
| Green Fluorescent Proteins | 1 | 2009 | 377 | 0.300 |
Why?
| Retinal Pigments | 1 | 2007 | 5 | 0.300 |
Why?
| Drug Administration Routes | 4 | 2009 | 41 | 0.300 |
Why?
| Photosensitizing Agents | 1 | 2008 | 26 | 0.300 |
Why?
| Medical Oncology | 1 | 2009 | 230 | 0.300 |
Why?
| Receptors, Glucocorticoid | 1 | 2009 | 144 | 0.300 |
Why?
| Lasers | 3 | 2021 | 121 | 0.290 |
Why?
| Anti-Infective Agents | 1 | 2010 | 225 | 0.290 |
Why?
| Anthraquinones | 1 | 2007 | 9 | 0.290 |
Why?
| Chemistry, Pharmaceutical | 4 | 2012 | 99 | 0.290 |
Why?
| Imidazolidines | 1 | 2007 | 8 | 0.290 |
Why?
| Indomethacin | 2 | 2004 | 75 | 0.290 |
Why?
| Fluorophotometry | 2 | 2020 | 3 | 0.290 |
Why?
| Dogs | 3 | 2012 | 341 | 0.280 |
Why?
| Macula Lutea | 1 | 2007 | 15 | 0.280 |
Why?
| ELAV-Like Protein 1 | 2 | 2017 | 20 | 0.280 |
Why?
| DNA | 2 | 2013 | 1356 | 0.280 |
Why?
| Microscopy, Electron, Scanning | 5 | 2005 | 194 | 0.280 |
Why?
| Rhodamines | 1 | 2006 | 17 | 0.280 |
Why?
| Mannitol | 1 | 2006 | 32 | 0.280 |
Why?
| Reproducibility of Results | 3 | 2022 | 2824 | 0.270 |
Why?
| Serum Albumin | 1 | 2007 | 135 | 0.270 |
Why?
| Blotting, Western | 7 | 2013 | 1153 | 0.260 |
Why?
| Protein Kinase Inhibitors | 1 | 2011 | 790 | 0.260 |
Why?
| Hydrogen-Ion Concentration | 5 | 2015 | 515 | 0.250 |
Why?
| Enzyme-Linked Immunosorbent Assay | 5 | 2013 | 795 | 0.250 |
Why?
| Aldehydes | 2 | 2005 | 144 | 0.250 |
Why?
| Superoxide Dismutase | 1 | 2007 | 332 | 0.250 |
Why?
| Time Factors | 12 | 2015 | 6171 | 0.250 |
Why?
| Triamcinolone Acetonide | 3 | 2021 | 27 | 0.240 |
Why?
| Cell Line, Tumor | 7 | 2022 | 2751 | 0.240 |
Why?
| Swine | 5 | 2021 | 706 | 0.240 |
Why?
| Glutathione | 2 | 2005 | 303 | 0.240 |
Why?
| Magnetic Resonance Spectroscopy | 3 | 2013 | 483 | 0.240 |
Why?
| Buserelin | 1 | 2004 | 1 | 0.240 |
Why?
| DNA Helicases | 2 | 2023 | 133 | 0.240 |
Why?
| Orphan Nuclear Receptors | 3 | 2014 | 14 | 0.230 |
Why?
| Oligopeptides | 3 | 2011 | 248 | 0.230 |
Why?
| Cell Membrane Permeability | 4 | 2018 | 83 | 0.230 |
Why?
| In Vitro Techniques | 6 | 2012 | 1044 | 0.220 |
Why?
| Lysosomes | 2 | 2015 | 125 | 0.220 |
Why?
| Mice, Inbred BALB C | 6 | 2014 | 1168 | 0.220 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 1003 | 0.220 |
Why?
| Half-Life | 3 | 2009 | 145 | 0.220 |
Why?
| Circular Dichroism | 2 | 2013 | 135 | 0.220 |
Why?
| Cell Cycle | 3 | 2013 | 546 | 0.220 |
Why?
| Respiratory System | 1 | 2004 | 141 | 0.210 |
Why?
| Octanols | 1 | 2022 | 2 | 0.210 |
Why?
| Polyesters | 3 | 2013 | 65 | 0.210 |
Why?
| Liposomes | 3 | 2011 | 149 | 0.210 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2002 | 45 | 0.210 |
Why?
| Linear Models | 3 | 2009 | 778 | 0.200 |
Why?
| Protein Structure, Secondary | 2 | 2013 | 327 | 0.200 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2002 | 36 | 0.200 |
Why?
| Temperature | 5 | 2004 | 587 | 0.200 |
Why?
| Protein Aggregates | 1 | 2022 | 66 | 0.200 |
Why?
| Prostatic Neoplasms | 1 | 2009 | 927 | 0.200 |
Why?
| alpha-Cyclodextrins | 1 | 2001 | 1 | 0.200 |
Why?
| Transfection | 3 | 2015 | 866 | 0.200 |
Why?
| Cyclodextrins | 1 | 2001 | 8 | 0.200 |
Why?
| Biocompatible Materials | 2 | 2020 | 378 | 0.200 |
Why?
| Chymotrypsin | 1 | 2001 | 20 | 0.200 |
Why?
| Thiazolidinediones | 2 | 2013 | 143 | 0.200 |
Why?
| Drug Evaluation, Preclinical | 4 | 2017 | 166 | 0.200 |
Why?
| Rhodopsin | 2 | 2011 | 9 | 0.200 |
Why?
| Electroretinography | 4 | 2018 | 40 | 0.190 |
Why?
| Models, Molecular | 2 | 2019 | 1390 | 0.190 |
Why?
| Cystinosis | 1 | 2021 | 1 | 0.190 |
Why?
| Brain | 2 | 2011 | 2373 | 0.190 |
Why?
| Contact Lenses | 1 | 2021 | 7 | 0.190 |
Why?
| Cystine | 1 | 2021 | 14 | 0.190 |
Why?
| Fluorescein Angiography | 4 | 2017 | 102 | 0.190 |
Why?
| Zinc Compounds | 2 | 1998 | 7 | 0.190 |
Why?
| Edetic Acid | 2 | 1998 | 44 | 0.190 |
Why?
| Oncogenes | 2 | 2022 | 104 | 0.190 |
Why?
| Carboplatin | 2 | 2013 | 139 | 0.190 |
Why?
| Respiratory Mucosa | 1 | 2003 | 258 | 0.180 |
Why?
| Uveitis | 2 | 2014 | 115 | 0.180 |
Why?
| Eye Burns | 2 | 2013 | 11 | 0.180 |
Why?
| Proteins | 2 | 2001 | 920 | 0.180 |
Why?
| Molecular Weight | 2 | 2013 | 329 | 0.180 |
Why?
| Hypromellose Derivatives | 1 | 2020 | 1 | 0.180 |
Why?
| Therapeutic Equivalency | 1 | 2020 | 18 | 0.180 |
Why?
| Collagen | 2 | 2013 | 416 | 0.180 |
Why?
| Mice, Nude | 3 | 2017 | 639 | 0.180 |
Why?
| Cytoskeleton | 1 | 2021 | 177 | 0.180 |
Why?
| Symporters | 1 | 2020 | 52 | 0.180 |
Why?
| Pyramidal Cells | 1 | 2020 | 51 | 0.180 |
Why?
| Corneal Stroma | 2 | 2018 | 16 | 0.180 |
Why?
| Prodrugs | 1 | 2000 | 43 | 0.180 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 68 | 0.180 |
Why?
| Cholic Acids | 2 | 2011 | 17 | 0.170 |
Why?
| Administration, Oral | 3 | 2012 | 734 | 0.170 |
Why?
| Ophthalmology | 1 | 2021 | 77 | 0.170 |
Why?
| Benzo(a)pyrene | 2 | 2013 | 7 | 0.170 |
Why?
| 2-Hydroxypropyl-beta-cyclodextrin | 3 | 2004 | 6 | 0.170 |
Why?
| Body Weight | 3 | 2011 | 867 | 0.170 |
Why?
| Thermodynamics | 1 | 2001 | 388 | 0.170 |
Why?
| Prednisolone | 2 | 2011 | 77 | 0.170 |
Why?
| Gene Expression Regulation | 6 | 2018 | 2353 | 0.170 |
Why?
| Mice, Inbred C57BL | 8 | 2018 | 4773 | 0.160 |
Why?
| Drug Monitoring | 1 | 2020 | 184 | 0.160 |
Why?
| Synovial Fluid | 1 | 1999 | 57 | 0.160 |
Why?
| Adsorption | 1 | 2019 | 125 | 0.160 |
Why?
| Chitosan | 2 | 2016 | 29 | 0.160 |
Why?
| Molecular Targeted Therapy | 2 | 2011 | 348 | 0.160 |
Why?
| Models, Biological | 3 | 2013 | 1646 | 0.160 |
Why?
| Glioma | 1 | 2022 | 296 | 0.160 |
Why?
| Drug Administration Schedule | 2 | 2011 | 724 | 0.150 |
Why?
| Chemistry, Physical | 2 | 2009 | 38 | 0.150 |
Why?
| Gene Silencing | 3 | 2017 | 175 | 0.150 |
Why?
| Cells, Cultured | 6 | 2018 | 3914 | 0.150 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2018 | 92 | 0.150 |
Why?
| Neovascularization, Pathologic | 2 | 2013 | 283 | 0.150 |
Why?
| Endoplasmic Reticulum | 2 | 2018 | 235 | 0.150 |
Why?
| Surface Properties | 1 | 2019 | 397 | 0.150 |
Why?
| Regional Blood Flow | 2 | 2011 | 428 | 0.150 |
Why?
| Drug Interactions | 3 | 2013 | 347 | 0.150 |
Why?
| Molecular Structure | 2 | 2009 | 447 | 0.150 |
Why?
| Glycoproteins | 1 | 1999 | 309 | 0.150 |
Why?
| Drug Combinations | 2 | 2011 | 289 | 0.150 |
Why?
| Action Potentials | 1 | 2020 | 410 | 0.150 |
Why?
| Excipients | 2 | 2001 | 49 | 0.140 |
Why?
| Turbinates | 2 | 2008 | 11 | 0.140 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2013 | 608 | 0.140 |
Why?
| Dextran Sulfate | 1 | 2016 | 70 | 0.140 |
Why?
| RNAi Therapeutics | 1 | 2016 | 3 | 0.140 |
Why?
| Mifepristone | 2 | 2009 | 65 | 0.140 |
Why?
| Folate Receptor 1 | 1 | 2016 | 13 | 0.140 |
Why?
| Surgeons | 1 | 2020 | 238 | 0.130 |
Why?
| Female | 16 | 2020 | 60018 | 0.130 |
Why?
| 2,4-Dinitrophenol | 3 | 2004 | 8 | 0.130 |
Why?
| Immunoconjugates | 1 | 2017 | 87 | 0.130 |
Why?
| Signal Transduction | 2 | 2013 | 4541 | 0.130 |
Why?
| Hippocampus | 1 | 2020 | 709 | 0.130 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 41 | 0.130 |
Why?
| Indazoles | 2 | 2017 | 58 | 0.130 |
Why?
| Central Nervous System | 1 | 1998 | 239 | 0.130 |
Why?
| Transient Receptor Potential Channels | 1 | 2015 | 3 | 0.130 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2015 | 13 | 0.130 |
Why?
| Precision Medicine | 1 | 2019 | 344 | 0.130 |
Why?
| Presenilin-1 | 1 | 2015 | 27 | 0.130 |
Why?
| Wnt3A Protein | 1 | 2015 | 7 | 0.120 |
Why?
| Cyclic AMP | 1 | 1996 | 227 | 0.120 |
Why?
| Receptors, LDL | 1 | 2015 | 39 | 0.120 |
Why?
| Mucous Membrane | 3 | 1996 | 109 | 0.120 |
Why?
| Blood Glucose | 3 | 2011 | 1824 | 0.120 |
Why?
| Sodium | 2 | 1996 | 183 | 0.120 |
Why?
| Absorption | 2 | 2004 | 52 | 0.120 |
Why?
| Administration, Intranasal | 2 | 2009 | 75 | 0.120 |
Why?
| Retinal Vessels | 1 | 2015 | 51 | 0.120 |
Why?
| Vaccine Potency | 1 | 2014 | 6 | 0.120 |
Why?
| Microbial Sensitivity Tests | 2 | 2010 | 299 | 0.120 |
Why?
| Aluminum Hydroxide | 1 | 2014 | 12 | 0.120 |
Why?
| Phagocytosis | 2 | 2013 | 355 | 0.120 |
Why?
| Injections, Intraperitoneal | 2 | 2004 | 104 | 0.120 |
Why?
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.120 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 317 | 0.120 |
Why?
| Plasminogen | 2 | 2011 | 32 | 0.120 |
Why?
| Eye Diseases, Hereditary | 1 | 2014 | 12 | 0.110 |
Why?
| Fibrosis | 2 | 2013 | 457 | 0.110 |
Why?
| Hepatitis B Vaccines | 1 | 2014 | 46 | 0.110 |
Why?
| Freezing | 1 | 2014 | 85 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 58 | 0.110 |
Why?
| Acetophenones | 1 | 2013 | 14 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 117 | 0.110 |
Why?
| Cholesterol | 2 | 2016 | 369 | 0.110 |
Why?
| Tight Junctions | 1 | 2014 | 68 | 0.110 |
Why?
| Withanolides | 1 | 2013 | 1 | 0.110 |
Why?
| Treatment Outcome | 6 | 2014 | 9162 | 0.110 |
Why?
| Calorimetry, Differential Scanning | 2 | 2004 | 34 | 0.110 |
Why?
| Retinal Rod Photoreceptor Cells | 1 | 2013 | 11 | 0.110 |
Why?
| Micro-Electrical-Mechanical Systems | 1 | 2013 | 5 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2015 | 148 | 0.110 |
Why?
| Chromatography, Gel | 1 | 2013 | 128 | 0.110 |
Why?
| alpha-Crystallin A Chain | 1 | 2013 | 8 | 0.110 |
Why?
| Cell Shape | 1 | 2013 | 54 | 0.110 |
Why?
| L-Lactate Dehydrogenase | 1 | 2013 | 107 | 0.110 |
Why?
| Capsid | 1 | 2013 | 76 | 0.110 |
Why?
| Vimentin | 1 | 2013 | 57 | 0.110 |
Why?
| Gemfibrozil | 1 | 2013 | 10 | 0.110 |
Why?
| Scattering, Radiation | 1 | 2013 | 91 | 0.110 |
Why?
| Monophenol Monooxygenase | 1 | 2012 | 9 | 0.110 |
Why?
| Trachea | 2 | 2005 | 233 | 0.110 |
Why?
| Corneal Injuries | 1 | 2013 | 34 | 0.110 |
Why?
| Madin Darby Canine Kidney Cells | 1 | 2012 | 14 | 0.110 |
Why?
| Receptors, Transferrin | 2 | 2017 | 22 | 0.110 |
Why?
| Adjuvants, Immunologic | 1 | 2014 | 206 | 0.110 |
Why?
| Levodopa | 1 | 2012 | 23 | 0.110 |
Why?
| Sensitivity and Specificity | 2 | 2008 | 1730 | 0.110 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 139 | 0.110 |
Why?
| Pressure | 1 | 2013 | 220 | 0.110 |
Why?
| Vision Disorders | 1 | 2014 | 130 | 0.100 |
Why?
| Timolol | 2 | 2011 | 14 | 0.100 |
Why?
| Bronchoalveolar Lavage | 1 | 2012 | 89 | 0.100 |
Why?
| Protein Stability | 1 | 2013 | 162 | 0.100 |
Why?
| Gels | 2 | 2002 | 72 | 0.100 |
Why?
| Ouabain | 3 | 1998 | 15 | 0.100 |
Why?
| Inflammation | 2 | 2020 | 2500 | 0.100 |
Why?
| Cell Count | 1 | 2013 | 305 | 0.100 |
Why?
| Corneal Diseases | 1 | 2012 | 34 | 0.100 |
Why?
| Doxycycline | 1 | 2012 | 56 | 0.100 |
Why?
| Lymphangiogenesis | 1 | 2012 | 24 | 0.100 |
Why?
| Colorimetry | 1 | 2012 | 14 | 0.100 |
Why?
| Pigmentation | 1 | 2012 | 55 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 193 | 0.100 |
Why?
| Hypolipidemic Agents | 1 | 2013 | 87 | 0.100 |
Why?
| Aqueous Humor | 2 | 2014 | 31 | 0.100 |
Why?
| Macaca fascicularis | 1 | 2012 | 51 | 0.100 |
Why?
| MicroRNAs | 1 | 2018 | 607 | 0.100 |
Why?
| Paclitaxel | 1 | 2013 | 192 | 0.100 |
Why?
| Cloning, Molecular | 1 | 2013 | 523 | 0.100 |
Why?
| Membrane Transport Proteins | 1 | 2013 | 137 | 0.100 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2017 | 704 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2018 | 847 | 0.100 |
Why?
| Computer Simulation | 2 | 2018 | 884 | 0.100 |
Why?
| Swine, Miniature | 1 | 2012 | 71 | 0.100 |
Why?
| Apoptosis | 4 | 2013 | 2377 | 0.100 |
Why?
| Microscopy, Phase-Contrast | 1 | 2011 | 19 | 0.100 |
Why?
| Drug Discovery | 1 | 2012 | 124 | 0.100 |
Why?
| Anti-Bacterial Agents | 2 | 2012 | 1485 | 0.100 |
Why?
| Carbon | 1 | 2012 | 159 | 0.100 |
Why?
| Carbonic Anhydrase Inhibitors | 1 | 2011 | 16 | 0.100 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2011 | 55 | 0.100 |
Why?
| Propranolol | 1 | 2011 | 53 | 0.100 |
Why?
| Amino Acids | 1 | 1995 | 454 | 0.090 |
Why?
| HEK293 Cells | 1 | 2013 | 602 | 0.090 |
Why?
| Quinoxalines | 1 | 2011 | 61 | 0.090 |
Why?
| Wound Healing | 1 | 2013 | 257 | 0.090 |
Why?
| Rats, Wistar | 1 | 2012 | 368 | 0.090 |
Why?
| Optic Nerve | 1 | 2011 | 65 | 0.090 |
Why?
| Curcumin | 1 | 2011 | 29 | 0.090 |
Why?
| Cross-Sectional Studies | 1 | 2021 | 4448 | 0.090 |
Why?
| Diffusion Chambers, Culture | 2 | 2010 | 6 | 0.090 |
Why?
| Biological Transport, Active | 4 | 2010 | 71 | 0.090 |
Why?
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 74 | 0.090 |
Why?
| Chemical Warfare Agents | 1 | 2012 | 121 | 0.090 |
Why?
| Ion Transport | 3 | 1996 | 55 | 0.090 |
Why?
| Gold | 2 | 2022 | 107 | 0.090 |
Why?
| Silymarin | 1 | 2012 | 194 | 0.090 |
Why?
| Materials Testing | 1 | 2012 | 356 | 0.090 |
Why?
| Lipogenesis | 1 | 2011 | 57 | 0.090 |
Why?
| Pregnadienediols | 1 | 2010 | 2 | 0.090 |
Why?
| Calorimetry | 1 | 2010 | 62 | 0.090 |
Why?
| Chromatography, Supercritical Fluid | 1 | 2009 | 3 | 0.090 |
Why?
| Leukocytes | 1 | 2011 | 281 | 0.090 |
Why?
| Neoplasms | 1 | 2023 | 2118 | 0.090 |
Why?
| Stress, Physiological | 1 | 2013 | 399 | 0.090 |
Why?
| Emulsions | 1 | 2009 | 44 | 0.090 |
Why?
| Graft Survival | 1 | 2012 | 480 | 0.080 |
Why?
| Interleukin-10 | 1 | 2011 | 299 | 0.080 |
Why?
| Polymorphism, Genetic | 1 | 2013 | 621 | 0.080 |
Why?
| Dosage Forms | 1 | 2009 | 10 | 0.080 |
Why?
| Calcium | 1 | 2015 | 1103 | 0.080 |
Why?
| Flow Cytometry | 2 | 2012 | 1083 | 0.080 |
Why?
| Blood Proteins | 1 | 2011 | 238 | 0.080 |
Why?
| Aging | 1 | 2019 | 1632 | 0.080 |
Why?
| Neoplasm Transplantation | 1 | 2009 | 235 | 0.080 |
Why?
| Retinal Neoplasms | 1 | 2009 | 21 | 0.080 |
Why?
| Genetic Vectors | 2 | 2007 | 290 | 0.080 |
Why?
| Retinoblastoma | 1 | 2009 | 26 | 0.080 |
Why?
| Anticholesteremic Agents | 1 | 2011 | 129 | 0.080 |
Why?
| Chick Embryo | 1 | 2009 | 122 | 0.080 |
Why?
| Vinblastine | 1 | 2009 | 61 | 0.080 |
Why?
| Drug Synergism | 1 | 2009 | 317 | 0.080 |
Why?
| Cell Membrane | 1 | 2012 | 683 | 0.080 |
Why?
| Least-Squares Analysis | 1 | 2008 | 73 | 0.080 |
Why?
| Calibration | 1 | 2008 | 129 | 0.080 |
Why?
| Tumor Burden | 1 | 2009 | 261 | 0.080 |
Why?
| Hydrocortisone | 1 | 2010 | 273 | 0.080 |
Why?
| Validation Studies as Topic | 1 | 2008 | 22 | 0.080 |
Why?
| Mice, Transgenic | 4 | 2018 | 1970 | 0.080 |
Why?
| Thionucleotides | 1 | 2007 | 34 | 0.080 |
Why?
| Lipid Metabolism | 1 | 2011 | 449 | 0.070 |
Why?
| Photochemotherapy | 1 | 2008 | 29 | 0.070 |
Why?
| Tosylphenylalanyl Chloromethyl Ketone | 2 | 1998 | 3 | 0.070 |
Why?
| Ethylmaleimide | 2 | 1998 | 18 | 0.070 |
Why?
| Cell Movement | 3 | 2017 | 867 | 0.070 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 193 | 0.070 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 174 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2007 | 84 | 0.070 |
Why?
| Doxorubicin | 1 | 2009 | 290 | 0.070 |
Why?
| Caveolae | 1 | 2007 | 16 | 0.070 |
Why?
| Macrophages | 2 | 2011 | 1284 | 0.070 |
Why?
| Clathrin | 1 | 2007 | 27 | 0.070 |
Why?
| Pharmaceutical Vehicles | 1 | 2007 | 11 | 0.070 |
Why?
| Models, Anatomic | 1 | 2008 | 92 | 0.070 |
Why?
| Galactose | 1 | 2007 | 20 | 0.070 |
Why?
| Species Specificity | 1 | 2008 | 552 | 0.070 |
Why?
| Mydriasis | 1 | 2007 | 9 | 0.070 |
Why?
| Vacuoles | 1 | 2007 | 33 | 0.070 |
Why?
| Software | 1 | 2011 | 541 | 0.070 |
Why?
| Cells | 1 | 2007 | 22 | 0.070 |
Why?
| Glycopeptides | 2 | 1998 | 43 | 0.070 |
Why?
| Burns, Chemical | 1 | 2007 | 25 | 0.070 |
Why?
| Pulmonary Alveoli | 1 | 2009 | 376 | 0.070 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 195 | 0.070 |
Why?
| Macaca mulatta | 1 | 2007 | 132 | 0.070 |
Why?
| Aptamers, Nucleotide | 1 | 2007 | 73 | 0.070 |
Why?
| Alzheimer Disease | 1 | 2011 | 438 | 0.070 |
Why?
| Ketorolac Tromethamine | 1 | 2006 | 3 | 0.070 |
Why?
| Diffusion | 2 | 2009 | 120 | 0.070 |
Why?
| Cell Hypoxia | 1 | 2007 | 220 | 0.070 |
Why?
| Mass Spectrometry | 1 | 2009 | 645 | 0.070 |
Why?
| Electrophysiology | 3 | 1996 | 202 | 0.070 |
Why?
| Hydrogels | 1 | 2012 | 581 | 0.060 |
Why?
| Kidney | 1 | 2012 | 1207 | 0.060 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 2005 | 20 | 0.060 |
Why?
| Lymph Nodes | 1 | 2008 | 423 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2005 | 27 | 0.060 |
Why?
| Hypoglycemic Agents | 1 | 2013 | 1008 | 0.060 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1361 | 0.060 |
Why?
| Dextrans | 2 | 2016 | 74 | 0.060 |
Why?
| Injections, Intramuscular | 1 | 2005 | 118 | 0.060 |
Why?
| Atherosclerosis | 1 | 2008 | 342 | 0.060 |
Why?
| Carcinogens | 1 | 2005 | 105 | 0.060 |
Why?
| Cyclooxygenase 1 | 1 | 2004 | 20 | 0.060 |
Why?
| Antibodies, Monoclonal | 1 | 2011 | 1265 | 0.060 |
Why?
| Oligoribonucleotides, Antisense | 1 | 2004 | 3 | 0.060 |
Why?
| Pharmaceutical Solutions | 1 | 2004 | 14 | 0.060 |
Why?
| X-Ray Diffraction | 1 | 2004 | 84 | 0.060 |
Why?
| Powders | 1 | 2004 | 38 | 0.060 |
Why?
| Cell Nucleus | 1 | 2007 | 553 | 0.060 |
Why?
| Immunohistochemistry | 3 | 2013 | 1642 | 0.060 |
Why?
| Diabetes Mellitus | 1 | 2011 | 908 | 0.060 |
Why?
| Cell Culture Techniques | 1 | 2006 | 344 | 0.060 |
Why?
| Predictive Value of Tests | 1 | 2008 | 1825 | 0.060 |
Why?
| Fluorescent Antibody Technique | 1 | 2004 | 398 | 0.050 |
Why?
| Cytochrome P-450 CYP2C8 | 2 | 2013 | 15 | 0.050 |
Why?
| Hormone Antagonists | 1 | 2003 | 38 | 0.050 |
Why?
| Cytosol | 1 | 2003 | 209 | 0.050 |
Why?
| Administration, Inhalation | 1 | 2004 | 644 | 0.050 |
Why?
| Middle Aged | 5 | 2018 | 27069 | 0.050 |
Why?
| Theranostic Nanomedicine | 1 | 2022 | 8 | 0.050 |
Why?
| Indocyanine Green | 1 | 2022 | 13 | 0.050 |
Why?
| Flow Injection Analysis | 1 | 2002 | 5 | 0.050 |
Why?
| Phototherapy | 1 | 2022 | 24 | 0.050 |
Why?
| Lipid Peroxidation | 1 | 2002 | 138 | 0.050 |
Why?
| Dialysis | 1 | 2002 | 24 | 0.050 |
Why?
| Verapamil | 1 | 2002 | 32 | 0.050 |
Why?
| Fuchs' Endothelial Dystrophy | 1 | 2021 | 1 | 0.050 |
Why?
| Chemical Precipitation | 1 | 2002 | 38 | 0.050 |
Why?
| Antiviral Agents | 1 | 2007 | 649 | 0.050 |
Why?
| Amino Acids, Aromatic | 1 | 2001 | 7 | 0.050 |
Why?
| Chronic Disease | 1 | 2008 | 1598 | 0.050 |
Why?
| Isoenzymes | 1 | 2003 | 285 | 0.050 |
Why?
| Capsules | 1 | 2002 | 36 | 0.050 |
Why?
| Vincristine | 1 | 2002 | 96 | 0.050 |
Why?
| Solutions | 1 | 2002 | 150 | 0.050 |
Why?
| Tetrazolium Salts | 1 | 2001 | 18 | 0.050 |
Why?
| Antimetabolites | 1 | 2001 | 21 | 0.050 |
Why?
| Indicators and Reagents | 1 | 2001 | 100 | 0.050 |
Why?
| Spectrometry, Fluorescence | 1 | 2001 | 158 | 0.050 |
Why?
| Ascorbic Acid | 1 | 2021 | 112 | 0.050 |
Why?
| Drug Design | 1 | 2022 | 156 | 0.050 |
Why?
| Thiazoles | 1 | 2001 | 110 | 0.050 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 263 | 0.050 |
Why?
| Cold Temperature | 1 | 2001 | 128 | 0.040 |
Why?
| Carcinogenesis | 1 | 2022 | 178 | 0.040 |
Why?
| Metal Nanoparticles | 1 | 2021 | 75 | 0.040 |
Why?
| Hydrolysis | 1 | 2000 | 179 | 0.040 |
Why?
| Liver X Receptors | 2 | 2011 | 30 | 0.040 |
Why?
| Stereoisomerism | 1 | 1999 | 91 | 0.040 |
Why?
| Microtubules | 1 | 2021 | 238 | 0.040 |
Why?
| Mannheimia haemolytica | 1 | 1999 | 1 | 0.040 |
Why?
| Receptor, TIE-2 | 1 | 2018 | 12 | 0.040 |
Why?
| Instillation, Drug | 1 | 2018 | 9 | 0.040 |
Why?
| Protein Conformation | 1 | 2001 | 822 | 0.040 |
Why?
| Streptozocin | 1 | 2018 | 16 | 0.040 |
Why?
| Fluorometry | 1 | 2018 | 19 | 0.040 |
Why?
| Tears | 1 | 2018 | 14 | 0.040 |
Why?
| Electroencephalography | 1 | 2020 | 365 | 0.040 |
Why?
| Membrane Proteins | 1 | 2004 | 1024 | 0.040 |
Why?
| Protein Binding | 1 | 2004 | 1917 | 0.040 |
Why?
| Dithiothreitol | 1 | 1998 | 17 | 0.040 |
Why?
| Random Allocation | 1 | 1999 | 337 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2018 | 140 | 0.040 |
Why?
| Antibiotics, Antineoplastic | 1 | 2018 | 114 | 0.040 |
Why?
| Olfactory Pathways | 1 | 1998 | 56 | 0.040 |
Why?
| Seizures | 1 | 2020 | 344 | 0.040 |
Why?
| Cerebrospinal Fluid | 1 | 1998 | 88 | 0.040 |
Why?
| Fatty Liver | 2 | 2011 | 217 | 0.040 |
Why?
| G1 Phase | 1 | 2017 | 68 | 0.040 |
Why?
| Static Electricity | 1 | 2017 | 117 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 84 | 0.040 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 156 | 0.030 |
Why?
| Visual Acuity | 1 | 2018 | 273 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1997 | 101 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 302 | 0.030 |
Why?
| Staining and Labeling | 1 | 2016 | 139 | 0.030 |
Why?
| Monosaccharide Transport Proteins | 1 | 1996 | 45 | 0.030 |
Why?
| Terbutaline | 1 | 1996 | 9 | 0.030 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 1996 | 17 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2016 | 149 | 0.030 |
Why?
| Colforsin | 1 | 1996 | 46 | 0.030 |
Why?
| Complement C3 | 1 | 2017 | 190 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| Theophylline | 1 | 1996 | 60 | 0.030 |
Why?
| Endocytosis | 1 | 2016 | 152 | 0.030 |
Why?
| Phosphodiesterase Inhibitors | 1 | 1996 | 82 | 0.030 |
Why?
| Analysis of Variance | 1 | 2018 | 1230 | 0.030 |
Why?
| Calcium Channel Blockers | 1 | 1996 | 115 | 0.030 |
Why?
| Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2015 | 6 | 0.030 |
Why?
| Folic Acid | 1 | 2016 | 159 | 0.030 |
Why?
| Adrenergic beta-Agonists | 1 | 1996 | 129 | 0.030 |
Why?
| Proteolysis | 1 | 2015 | 145 | 0.030 |
Why?
| Hemoglobins | 1 | 2017 | 312 | 0.030 |
Why?
| Epinephrine | 1 | 1996 | 167 | 0.030 |
Why?
| Hepatitis B Surface Antigens | 1 | 2014 | 19 | 0.030 |
Why?
| Zonula Occludens-1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| Matrix Metalloproteinase Inhibitors | 1 | 2014 | 13 | 0.030 |
Why?
| Cycloheximide | 1 | 2014 | 56 | 0.030 |
Why?
| ortho-Aminobenzoates | 1 | 1993 | 7 | 0.030 |
Why?
| Barium Compounds | 1 | 1993 | 7 | 0.030 |
Why?
| Protein Synthesis Inhibitors | 1 | 2014 | 44 | 0.030 |
Why?
| Chloride Channels | 1 | 1993 | 35 | 0.030 |
Why?
| Fundus Oculi | 1 | 2013 | 40 | 0.030 |
Why?
| Tenon Capsule | 1 | 2013 | 3 | 0.030 |
Why?
| Diuretics | 1 | 1993 | 67 | 0.030 |
Why?
| Arginine | 1 | 1995 | 241 | 0.030 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2013 | 18 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2013 | 49 | 0.030 |
Why?
| Ion Channels | 1 | 1993 | 123 | 0.030 |
Why?
| Autophagy | 1 | 2015 | 236 | 0.030 |
Why?
| Lipofuscin | 1 | 2012 | 2 | 0.030 |
Why?
| Pepstatins | 1 | 2012 | 4 | 0.030 |
Why?
| Haplorhini | 1 | 2013 | 60 | 0.030 |
Why?
| Cathepsin D | 1 | 2012 | 14 | 0.030 |
Why?
| beta Catenin | 1 | 2015 | 220 | 0.030 |
Why?
| RNA Interference | 1 | 2015 | 438 | 0.030 |
Why?
| Opsins | 1 | 2012 | 10 | 0.030 |
Why?
| Boron Compounds | 1 | 2012 | 17 | 0.030 |
Why?
| Antibody Formation | 1 | 2014 | 273 | 0.030 |
Why?
| Glaucoma Drainage Implants | 1 | 2013 | 47 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 112 | 0.030 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2013 | 174 | 0.030 |
Why?
| Immunoblotting | 1 | 2012 | 281 | 0.030 |
Why?
| Irritants | 1 | 2012 | 41 | 0.030 |
Why?
| Adult | 4 | 2018 | 30789 | 0.030 |
Why?
| Caspase 3 | 1 | 2013 | 237 | 0.030 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 139 | 0.020 |
Why?
| Catalytic Domain | 1 | 2012 | 202 | 0.020 |
Why?
| Mechlorethamine | 1 | 2012 | 64 | 0.020 |
Why?
| Homeostasis | 1 | 2015 | 577 | 0.020 |
Why?
| Brimonidine Tartrate | 1 | 2011 | 9 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 1996 | 2000 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2014 | 804 | 0.020 |
Why?
| Rats, Transgenic | 1 | 2011 | 15 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 287 | 0.020 |
Why?
| Desmosterol | 1 | 2011 | 1 | 0.020 |
Why?
| Androstenes | 1 | 2011 | 11 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2011 | 105 | 0.020 |
Why?
| Cross-Over Studies | 1 | 2013 | 435 | 0.020 |
Why?
| COS Cells | 1 | 2011 | 175 | 0.020 |
Why?
| Laser Coagulation | 1 | 2011 | 54 | 0.020 |
Why?
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 20 | 0.020 |
Why?
| Hep G2 Cells | 1 | 2011 | 61 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 1996 | 2790 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1147 | 0.020 |
Why?
| Mustard Gas | 1 | 2012 | 117 | 0.020 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2011 | 155 | 0.020 |
Why?
| Antibodies, Viral | 1 | 2014 | 527 | 0.020 |
Why?
| Phosphorylation | 1 | 2015 | 1571 | 0.020 |
Why?
| Young Adult | 2 | 2018 | 10518 | 0.020 |
Why?
| Intestinal Absorption | 1 | 1991 | 93 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2012 | 402 | 0.020 |
Why?
| Mutagenesis, Site-Directed | 1 | 2011 | 346 | 0.020 |
Why?
| Immunoglobulin G | 1 | 2014 | 781 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2013 | 1243 | 0.020 |
Why?
| Membrane Potentials | 1 | 2010 | 251 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2012 | 962 | 0.020 |
Why?
| Ketorolac | 1 | 2009 | 17 | 0.020 |
Why?
| RNA, Ribosomal, 18S | 1 | 2009 | 22 | 0.020 |
Why?
| Gene Amplification | 1 | 2009 | 96 | 0.020 |
Why?
| ATP Binding Cassette Transporter 1 | 1 | 2008 | 10 | 0.020 |
Why?
| Foam Cells | 1 | 2008 | 13 | 0.020 |
Why?
| Sterol Regulatory Element Binding Protein 1 | 1 | 2008 | 54 | 0.020 |
Why?
| Mice, Knockout | 1 | 2015 | 2604 | 0.020 |
Why?
| Hypertriglyceridemia | 1 | 2008 | 34 | 0.020 |
Why?
| Feces | 1 | 2011 | 372 | 0.020 |
Why?
| Fibroblasts | 1 | 2013 | 839 | 0.020 |
Why?
| Apolipoproteins E | 1 | 2008 | 81 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2011 | 1001 | 0.020 |
Why?
| DNA Primers | 1 | 2009 | 514 | 0.020 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2008 | 123 | 0.020 |
Why?
| Intestines | 1 | 2011 | 324 | 0.020 |
Why?
| Sodium Hydroxide | 1 | 2007 | 8 | 0.020 |
Why?
| Cell Fractionation | 1 | 2007 | 53 | 0.020 |
Why?
| Receptors, Peptide | 1 | 2007 | 21 | 0.020 |
Why?
| Nerve Tissue Proteins | 1 | 2011 | 535 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2011 | 576 | 0.020 |
Why?
| Models, Theoretical | 1 | 2010 | 520 | 0.020 |
Why?
| Cytomegalovirus | 1 | 2007 | 146 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2009 | 826 | 0.020 |
Why?
| Biomedical Research | 1 | 2010 | 589 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2011 | 2586 | 0.010 |
Why?
| Phloretin | 1 | 1996 | 1 | 0.010 |
Why?
| Phlorhizin | 1 | 1996 | 2 | 0.010 |
Why?
| Levobunolol | 1 | 1993 | 1 | 0.010 |
Why?
| Betaxolol | 1 | 1993 | 2 | 0.010 |
Why?
| Atenolol | 1 | 1993 | 6 | 0.010 |
Why?
| Nasolacrimal Duct | 1 | 1993 | 7 | 0.010 |
Why?
| Kinetics | 1 | 1996 | 1569 | 0.010 |
Why?
| Glucose | 1 | 1996 | 904 | 0.010 |
Why?
| Aged | 1 | 2009 | 19294 | 0.010 |
Why?
|
|
Kompella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|